165 related articles for article (PubMed ID: 34781823)
21. Reexpression of tumor suppressor, sFRP1, leads to antitumor synergy of combined HDAC and methyltransferase inhibitors in chemoresistant cancers.
Cooper SJ; von Roemeling CA; Kang KH; Marlow LA; Grebe SK; Menefee ME; Tun HW; Colon-Otero G; Perez EA; Copland JA
Mol Cancer Ther; 2012 Oct; 11(10):2105-15. PubMed ID: 22826467
[TBL] [Abstract][Full Text] [Related]
22. Knockdown of the Wnt receptor Frizzled-1 (FZD1) reduces MDR1/P-glycoprotein expression in multidrug resistant leukemic cells and inhibits leukemic cell proliferation.
Wang YH; Imai Y; Shiseki M; Tanaka J; Motoji T
Leuk Res; 2018 Apr; 67():99-108. PubMed ID: 29482174
[TBL] [Abstract][Full Text] [Related]
23. MiRNA-30a-mediated autophagy inhibition sensitizes renal cell carcinoma cells to sorafenib.
Zheng B; Zhu H; Gu D; Pan X; Qian L; Xue B; Yang D; Zhou J; Shan Y
Biochem Biophys Res Commun; 2015 Apr; 459(2):234-239. PubMed ID: 25712526
[TBL] [Abstract][Full Text] [Related]
24. FZD1 activates protein kinase C delta-mediated drug-resistance in multidrug-resistant MES-SA/Dx5 cancer cells.
Hung TH; Chen CM; Tseng CP; Shen CJ; Wang HL; Choo KB; Chong KY
Int J Biochem Cell Biol; 2014 Aug; 53():55-65. PubMed ID: 24814288
[TBL] [Abstract][Full Text] [Related]
25. PDIA6 promotes pancreatic cancer progression and immune escape through CSN5-mediated deubiquitination of β-catenin and PD-L1.
Ma Y; Xia P; Wang Z; Xu J; Zhang L; Jiang Y
Neoplasia; 2021 Sep; 23(9):912-928. PubMed ID: 34325342
[TBL] [Abstract][Full Text] [Related]
26. Silencing Livin induces apoptotic and autophagic cell death, increasing chemotherapeutic sensitivity to cisplatin of renal carcinoma cells.
Wang Z; Liu S; Ding K; Ding S; Li C; Lu J; Gao D; Zhang T; Bi D
Tumour Biol; 2016 Nov; 37(11):15133-15143. PubMed ID: 27677286
[TBL] [Abstract][Full Text] [Related]
27. Targeting RAD51 enhances chemosensitivity of adult T‑cell leukemia‑lymphoma cells by reducing DNA double‑strand break repair.
Yang M; Tian X; Fan Z; Yu W; Li Z; Zhou J; Zhang W; Liang A
Oncol Rep; 2019 Dec; 42(6):2426-2434. PubMed ID: 31638261
[TBL] [Abstract][Full Text] [Related]
28. The Inhibitory Effect of PDIA6 Downregulation on Bladder Cancer Cell Proliferation and Invasion.
Cheng HP; Liu Q; Li Y; Li XD; Zhu CY
Oncol Res; 2017 Apr; 25(4):587-593. PubMed ID: 27760590
[TBL] [Abstract][Full Text] [Related]
29. Antiproliferative effects of imatinib mesylate on ZR‑75‑1 and MDA‑MB‑231 cell lines via PDGFR‑β, PDGF‑BB, c‑Kit and SCF expression.
Kadivar A; Ibrahim Noordin M; Aditya A; Kamalidehghan B; Davoudi ET; Sedghi R; Akbari Javar H
Int J Mol Med; 2018 Jul; 42(1):414-424. PubMed ID: 29620139
[TBL] [Abstract][Full Text] [Related]
30. PDIA6 contributes to aerobic glycolysis and cancer progression in oral squamous cell carcinoma.
Mao L; Wu X; Gong Z; Yu M; Huang Z
World J Surg Oncol; 2021 Mar; 19(1):88. PubMed ID: 33761940
[TBL] [Abstract][Full Text] [Related]
31. BRDT is a novel regulator of eIF4EBP1 in renal cell carcinoma.
Wan P; Chen Z; Zhong W; Jiang H; Huang Z; Peng D; He Q; Chen N
Oncol Rep; 2020 Dec; 44(6):2475-2486. PubMed ID: 33125143
[TBL] [Abstract][Full Text] [Related]
32. miR-124 represses FZD5 to attenuate P-glycoprotein-mediated chemo-resistance in renal cell carcinoma.
Long QZ; Du YF; Liu XG; Li X; He DL
Tumour Biol; 2015 Sep; 36(9):7017-26. PubMed ID: 25861751
[TBL] [Abstract][Full Text] [Related]
33. TCF7 knockdown inhibits the imatinib resistance of chronic myeloid leukemia K562/G01 cells by neutralizing the Wnt/β‑catenin/TCF7/ABC transporter signaling axis.
Zhang H; Wang Y; Yang H; Huang Z; Wang X; Feng W
Oncol Rep; 2021 Feb; 45(2):557-568. PubMed ID: 33416164
[TBL] [Abstract][Full Text] [Related]
34. Cytotoxic effect of 6-Shogaol in Imatinib sensitive and resistant K562 cells.
Ozkan T; Hekmatshoar Y; Pamuk H; Ozcan M; Yaman G; Yagiz GC; Akdemir C; Sunguroglu A
Mol Biol Rep; 2021 Feb; 48(2):1625-1631. PubMed ID: 33515349
[TBL] [Abstract][Full Text] [Related]
35. A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2.
Dai Y; Rahmani M; Corey SJ; Dent P; Grant S
J Biol Chem; 2004 Aug; 279(33):34227-39. PubMed ID: 15175350
[TBL] [Abstract][Full Text] [Related]
36. Overexpression of
Deng Y; Li X; Feng J; Zhang X
Biosci Rep; 2018 Jun; 38(3):. PubMed ID: 29559564
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of the Nrf2-TrxR Axis Sensitizes the Drug-Resistant Chronic Myelogenous Leukemia Cell Line K562/G01 to Imatinib Treatments.
Xu L; Zhao Y; Pan F; Zhu M; Yao L; Liu Y; Feng J; Xiong J; Chen X; Ren F; Tan Y; Wang H
Biomed Res Int; 2019; 2019():6502793. PubMed ID: 31828114
[TBL] [Abstract][Full Text] [Related]
38. BEX1 promotes imatinib-induced apoptosis by binding to and antagonizing BCL-2.
Xiao Q; Hu Y; Liu Y; Wang Z; Geng H; Hu L; Xu D; Wang K; Zheng L; Zheng S; Ding K
PLoS One; 2014; 9(3):e91782. PubMed ID: 24626299
[TBL] [Abstract][Full Text] [Related]
39. Receptor tyrosine kinase-like orphan receptor 2 (Ror2) expression creates a poised state of Wnt signaling in renal cancer.
Rasmussen NR; Wright TM; Brooks SA; Hacker KE; Debebe Z; Sendor AB; Walker MP; Major MB; Green J; Wahl GM; Rathmell WK
J Biol Chem; 2013 Sep; 288(36):26301-26310. PubMed ID: 23893409
[TBL] [Abstract][Full Text] [Related]
40. PON1 hypermethylation is associated with progression of renal cell carcinoma.
Li X; Yu Q
J Cell Mol Med; 2019 Oct; 23(10):6646-6657. PubMed ID: 31400051
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
